Rhode Island Chronicle

DelveInsight’s, “Ulcerative Colitis Pipeline Insight 2023” report provides comprehensive insights about 110+ companies and 110+ pipeline drugs in the Ulcerative Colitis pipeline landscape. It covers the Ulcerative Colitis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Ulcerative Colitis pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Key Takeaways from the Ulcerative Colitis Pipeline Report

• DelveInsight’s Ulcerative Colitis pipeline report depicts a robust space with 110+ active players working to develop 110+ pipeline therapies for Ulcerative Colitis treatment.
• The leading companies working in the Ulcerative Colitis Market include Eli Lilly and Company, Lipid Therapeutics, Hoffmann-La Roche, Arena Pharmaceuticals, InDex Pharmaceuticals, EA Pharma, Theravance Biopharma, Boehringer Ingelheim, Janssen Research & Development, Lycera, LG Chem, Iltoo Pharma, Immunic, Hutchison Medipharma, Tianjin Hemay Pharmaceutical, GlaxoSmithKline, Galapagos, Celgene, Gossamer Bio, Eisai, UCB, Suzhou Connect Biopharmaceuticals, Landos Biopharma, Seres Therapeutics, bivax, Genentech, ParaTech A/S, I-Mab Biopharma, Sublimity Therapeutics Holdco, Reistone Biopharma, Qu Biologics, PurGenesis Technologies, Protagonist Therapeutics, Pfizer, Palobiofarma, Novartis Pharmaceuticals, Bristol-Myers Squibb, Bridge Biotherapeutics, Amgen, Allergan, Applied Molecular Transport, AbGenomics International, Protalix BioTherapeutics, LTT Bio-Pharma Co Ltd, Dongwha pharma, Seres Therapeutics, Innovation Pharmaceuticals, Holy Stone Healthcare, SLA Pharma, OSE Immunotherapeutics, and others.
• Promising Ulcerative Colitis Pipeline Therapies in the various stages of development include ABX464, Etrasimod, Adalimumab, Tralokinumab, BBT-401-1S or Placebo, Filgotinib, Mesalazine, Asacol®, and others.
• January 2023, Galapagos NV announced a study of Phase 3 Clinical Trials for Filgotinib. The primary objective of this study is to observe the long-term safety of filgotinib in adults who have completed or met protocol specified efficacy discontinuation criteria in a prior filgotinib treatment study in ulcerative colitis (UC).
• September 2023, Pfizer announced a study of Phase 2 Clinical Trials for Etrasimod. The purpose of this Japan-only study is to assess the safety and efficacy of etrasimod at 2 doses in Japanese subjects with moderately to severely active ulcerative colitis (UC) when administered for 12 weeks.

Request a sample and discover the recent advances in Ulcerative Colitis Treatment Drugs @ Ulcerative Colitis Pipeline Report

The Ulcerative Colitis pipeline report provides detailed profiles of pipeline assets, a comparative analysis of clinical and non-clinical stage Ulcerative Colitis drugs, inactive and dormant assets, a comprehensive assessment of driving and restraining factors, and an assessment of opportunities and risks in the Ulcerative Colitis clinical trial landscape.

Ulcerative Colitis Overview

Ulcerative colitis is a chronic disease of the large intestine, in which the lining of the colon become inflamed and develops tiny open sores or ulcers. Those ulcers produce pus and mucous, which causes abdominal pain.

Find out more about Ulcerative Colitis Treatment Drugs @ Drugs for Ulcerative Colitis Treatment

Ulcerative Colitis Emerging Drugs Profile

• Mirikizumab: Eli Lilly and Company
• Risankizumab: AbbVie
• Etrasimod: Pfizer

Ulcerative Colitis Pipeline Therapeutics Assessment

There are approx. 110+ key companies which are developing the therapies for Ulcerative Colitis. The Ulcerative Colitis companies which have their Ulcerative Colitis drug candidates in the most advanced stage, i.e. Preregistration include, Gilead Sciences.

Learn more about the emerging Ulcerative Colitis Pipeline Therapies @ Ulcerative Colitis Clinical Trials Assessment

Scope of the Ulcerative Colitis Pipeline Report

• Coverage- Global
• Ulcerative Colitis Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Ulcerative Colitis Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
• Ulcerative Colitis Companies- Eli Lilly and Company, Lipid Therapeutics, Hoffmann-La Roche, Arena Pharmaceuticals, InDex Pharmaceuticals, EA Pharma, Theravance Biopharma, Boehringer Ingelheim, Janssen Research & Development, Lycera, LG Chem, Iltoo Pharma, Immunic, Hutchison Medipharma, Tianjin Hemay Pharmaceutical, GlaxoSmithKline, Galapagos, Celgene, Gossamer Bio, Eisai, UCB, Suzhou Connect Biopharmaceuticals, Landos Biopharma, Seres Therapeutics, bivax, Genentech, ParaTech A/S, I-Mab Biopharma, Sublimity Therapeutics Holdco, Reistone Biopharma, Qu Biologics, PurGenesis Technologies, Protagonist Therapeutics, Pfizer, Palobiofarma, Novartis Pharmaceuticals, Bristol-Myers Squibb, Bridge Biotherapeutics, Amgen, Allergan, Applied Molecular Transport, AbGenomics International, Protalix BioTherapeutics, LTT Bio-Pharma Co Ltd, Dongwha pharma, Seres Therapeutics, Innovation Pharmaceuticals, Holy Stone Healthcare, SLA Pharma, OSE Immunotherapeutics, and others.
• Ulcerative Colitis Pipeline Therapies- ABX464, Etrasimod, Adalimumab, Tralokinumab, BBT-401-1S or Placebo, Filgotinib, Mesalazine, Asacol®, and others.

Dive deep into rich insights for new drugs for Ulcerative Colitis Treatment, Visit @ Ulcerative Colitis Market Drivers and Barriers, and Future Perspective

Table of Content

1. Introduction
2. Executive Summary
3. Ulcerative Colitis: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Ulcerative Colitis– DelveInsight’s Analytical Perspective
7. In-depth Commercial Assessment
8. Ulcerative Colitis Collaboration Deals
9. Late Stage Products (Preregistration)
10. Mirikizumab: Eli Lilly and Company
11. Drug profiles in the detailed report…..
12. Late Stage Products (Phase III)
13. Upadacitinib: AbbVie
14. Drug profiles in the detailed report…..
15. Mid Stage Products (Phase II/III)
16. TD-1473: Theravance Biopharma
17. Drug profiles in the detailed report…..
18. Mid Stage Products (Phase II)
19. LYC-30937: Lycera
20. Drug profiles in the detailed report…..
21. Early Stage Products (Phase I/II)
22. Remestemcel-L: Mesoblast
23. Drug profiles in the detailed report…..
24. Early Stage Products (Phase I)
25. OPL-002: Oppilan Pharma
26. Drug profiles in the detailed report…..
27. IND Stage Products
28. SVT-1A710: Servatus
29. Drug profiles in the detailed report…..
30. Preclinical Stage Products
31. ATH-001: Athos Therapeutics
32. Drug profiles in the detailed report…..
33. Discovery Stage Products
34. NM 001: NuMedii
35. Inactive Products
36. Ulcerative Colitis Key Companies
37. Ulcerative Colitis Key Products
38. Ulcerative Colitis- Unmet Needs
39. Ulcerative Colitis- Market Drivers and Barriers
40. Ulcerative Colitis- Future Perspectives and Conclusion
41. Ulcerative Colitis Analyst Views
42. Ulcerative Colitis Key Companies
43. Appendix

For further information on the Ulcerative Colitis Pipeline therapeutics, reach out to Ulcerative Colitis Unmet Needs and Analyst Views

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting